FDA allows Suven Life Sciences to manufacture bulk drugs
The decision is followed by renewal inspection by a team from the regulatory agency. Suven Life Sciences is an India-based contract research and manufacturing services (CRAMS) provider, which
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
RE-LY is a PROBE (prospective, randomised, open-label with blinded endpoint evaluation), designed to compare two fixed doses of the oral direct thrombin inhibitor dabigatran (110mg and 150mg bid)
Besides, a product portfolio of over 100 research-based ELISA kits that cover research categories such as angiogenesis, apoptosis, endocrinology, immunology, inflammation, oncology and signal transduction will also be